🇺🇸 FDA
Pipeline program

Valemetostat Tosylate, Golcadomide, RITUXIMAB, Valemetostat Tosylate, Golcadomide, RITUXIMAB, Golcadomide

CC-99282-NHL-001

Phase 2 small_molecule active

Quick answer

Valemetostat Tosylate, Golcadomide, RITUXIMAB, Valemetostat Tosylate, Golcadomide, RITUXIMAB, Golcadomide for Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma is a Phase 2 program (small_molecule) at Celgene Europe Limited with 1 ClinicalTrials.gov record(s).

Program details

Company
Celgene Europe Limited
Indication
Follicular B-cell non-Hodgkin's lymphoma, Primary central nervous system lymphoma, Marginal zone lymphoma, Diffuse large B-cell lymphoma, Mantle cell lymphoma
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials